Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price cuts while a bumper profit haul from its Mounjaro rival Eli Lilly left it trailing behind. Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results